Diaceutics Plc

As of December 31, 2025, Diaceutics Plc carries a market capitalization of 10.84B, placing it among publicly traded companies globally. Its enterprise value stands at 10.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Diaceutics Plc's next confirmed earnings release is scheduled for March 15, 2027.

As of December 31, 2025, Diaceutics Plc has 84.66M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Diaceutics Plc maintains a current ratio of 3.43, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Diaceutics Plc's stock has gained approximately 22.42% over the past 52 weeks. The 50-day moving average sits at 172.87, while the 200-day moving average is 158.10.

As of December 31, 2025, Diaceutics Plc holds 734.40M in cash and equivalents against 115.20M in total debt, resulting in a net debt position of -734.40M. Total book value stands at 4.05B, with working capital of 2.08B providing operational flexibility.